Quotables
"The wireless music box has no imaginable commercial value. Who would pay for a message sent to nobody in particular?"
David Sarnoff, American radio pioneer ; 1921
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8163294 | Growth regulatable recombinant BCG compositions Immunogenic compositions comprising growth regulatable recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions... | 04/24/2012 |
| 8147850 | Immunogenic constructs The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p1... | 04/03/2012 |
| 8142797 | Therapeutic TB vaccine Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis. ... | 03/27/2012 |
| 8128941 | Assay for detecting tuberculosis in nonhuman primates Systems, methods, and compositions for a diagnostic method for detecting TB in non-human primates that is easy to use, sensitive, and specific. The method utilizes recombinant mycobacterial antigens, such as polyfusion proteins. The method utilizes an antigen-antibo... | 03/06/2012 |
| 8110200 | Fusion proteins of The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera ... | 02/07/2012 |
| 8110201 | Fusion proteins of mycobacterium tuberculosis The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera ... | 02/07/2012 |
| 8105614 | Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves by immunizing with pools of overlapping fragments... | 01/31/2012 |
| 8101192 | Methods for producing an immune response to tuberculosis Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb,... | 01/24/2012 |
| 8101191 | Mycobacterial SecA2 mutants Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a m... | 01/24/2012 |
| 8101193 | Tuberculosis vaccines comprising antigens expressed during the latent infection phase The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immu... | 01/24/2012 |
| 8084041 | Use of mycrobacterial vaccines in CD4 or CD8 lymphocyte-deficient mammals Methods of treating a mammal that is deficient in CD4+ and/or CD8+ lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in the M. tuberculosis complex. In these methods, the mycobacterium... | 12/27/2011 |
| 8084042 | Compounds and methods for immunotherapy and diagnosis of tuberculosis Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such... | 12/27/2011 |
| 8067016 | Fusion proteins of The present invention relates to fusion proteins containing at least two Mycobacterium species antigens. In particular, it relates to nucleic acids encoding fusion proteins that include two or more individual M. tuberculosis antigens, which increase se... | 11/29/2011 |
| 8048434 | Vaccine adjuvants The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when a... | 11/01/2011 |
| 8029806 | Method for diagnosing of The present invention relates to a method and a kit for detecting Mycobacterium tuberculosis (MTB) or Nontuberculous mycobacteria (NTM) of patients. The present invention also relates to primers and probes used to detect Mycobacterium tuberculosis (MTB... | 10/04/2011 |
| 8021671 | Pro-apoptotic bacterial vaccines to enhance cellular immune responses Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner th... | 09/20/2011 |
| 8012492 | In vitro model of latent mycobacterial infection A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrien... | 09/06/2011 |
| 7993657 | Antibody profiles characteristic of tuberculosis state Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination of at least three M. tuberculosis protein antigens, at least one for which a positive response is consistent with inactive TB and at least one f... | 08/09/2011 |
| 7993658 | Targeting of triacylclycerol synthase gene for tuberculosis treatment Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides... | 08/09/2011 |
| 7988980 | Tuberculosis vaccine with improved efficacy The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with ... | 08/02/2011 |
| 7972609 | Method of treating cancer Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from ‘Mycobacterium w’ (Mw) is found to be useful in the management of cancer. We have now found that the same therape... | 07/05/2011 |
| 7968105 | Tuberculosis vaccines comprising antigens expressed during the latent infection phase The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic... | 06/28/2011 |
| 7939089 | Attenuated mycobacteria as vectors for gene delivery to mammalian cells Provided are mycobacteria comprising a recombinant gene operably liked to a mammalian promoter that directs expression of the recombinant gene from a mammalian cell. Also provided are mammalian cells comprising the above mycobacteria. Additionally provided are mycob... | 05/10/2011 |
| 7935354 | Generation of new BCG vaccine strains protecting against the establishment of latent infection and reactivation from the latent or persistent state A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR re... | 05/03/2011 |
| 7935353 | Compounds and methods for diagnosis and immunotherapy of tuberculosis Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA m... | 05/03/2011 |
| 7927609 | Compounds and methods for immunotherapy and diagnosis of tuberculosis Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polype... | 04/19/2011 |
| 7927610 | Compounds and methods for diagnosis and immunotherapy of tuberculosis Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA m... | 04/19/2011 |
| 7927611 | Compounds and methods for diagnosis and immunotherapy of tuberculosis Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA m... | 04/19/2011 |
| 7892566 | Immunogenic constructs The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a pl... | 02/22/2011 |
| 7883712 | Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of BCG and The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These str... | 02/08/2011 |
| 7871627 | Gram positive bacteria preparations for the treatment of disease comprising an immune dysregulation Compositions comprising components prepared from Gram positive bacteria such as Gram positive facultative intra-cellular bacteria, for example mycobacteria, including extended freeze-dried killed Gram positive bacteria, their method of preparation and their use in h... | 01/18/2011 |
| 7867502 | Tuberculosis vaccine and diagnostics based on the sat-6 gene family This invention relates to a polypeptide fragment which comprises an amino acid sequence encoded by a member of the esat-6 gene. A member of the esat-6 gene family is defined as gene encoding a small protein and that two such genes are arranged next to each other on ... | 01/11/2011 |
| 7858102 | Compositions for eliciting an immune response against subspecies The invention provides compositions and method for stimulating an immunological response against Mycobacterium avium subspecies paratuberculosis (MPT). The compositions comprise at least five recombinant immunogenic components. The immunogenic componen... | 12/28/2010 |
| 7850979 | Compositions for immunizing against mycobacterium A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses... | 12/14/2010 |
| 7842299 | Methods for producing an immune response to tuberculosis Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb,... | 11/30/2010 |
| 7838013 | Specific epitope based immunological diagnosis of tuberculosis The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and i... | 11/23/2010 |
| 7829104 | Electroporation of and overexpression of antigens in mycobacteria Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains d... | 11/09/2010 |
| 7829103 | Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for preparing such a sequence, the sequence being previously produced in a... | 11/09/2010 |
| 7811588 | Mycobacterial genes down-regulated during latency A method is provided for identifying mycobacterial genes the expression of which is down-regulated during a stationary phase culture of mycobacteria under nutrient-starving conditions when compared with an exponential phase culture of mycobacteria under culture cond... | 10/12/2010 |
| 7807182 | Early detection of mycobacterial disease using peptides A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical dis... | 10/05/2010 |
